Alle Storys
Folgen
Keine Story von Isotechnika Inc. mehr verpassen.

Isotechnika Inc.

Isotechnika Receives European Patent for Lead Immunosuppressive Drug, ISA247

Edmonton, Canada (ots/PRNewswire)

Isotechnika Inc. announced
today that the Company has been issued  European Patent No. EP0991660
for its lead immunosuppressive drug, ISA247.  The patent entitled
"DEUTERATED AND UNDEUTERATED CYCLOSPORINE ANALOGS AND  THEIR USE AS
IMMUNOMODULATING AGENTS" is the ninth patent to be issued
internationally in this patent family. Patents relating to these
claims  have issued in the following countries; Australia (No.
750245, issued July  11, 2002 and No. 774744 issued October 21,
2004), Canada (No. 2,298,572  issued April 9, 2002 and No. 2,372,639
issued November 1, 2005); New  Zealand (No. 502362 issued September
6, 2001), South Korea (No. 585348,  issued June 1, 2006) and the
United States (No. 6,605,593 issued August 12,  2003 and No.
6,613,739 issued September 2, 2003).
"We are pleased to add another international patent in a major
market  to our portfolio," stated Dr. Randall Yatscoff, Isotechnika's
President and  Chief Executive Officer. "Several additional
patentable claims for ISA247  continue to be investigated and pursued
where appropriate."
About Isotechnika
Isotechnika Inc. is an international biopharmaceutical company
headquartered in Edmonton, Alberta, Canada. Drawing upon its
expertise in  medicinal chemistry and immunology, the Company is
focused on the discovery  and development of novel immunosuppressive
therapeutics that are safer than  currently available treatments. Its
entrepreneurial management and world- class team of scientists are
building a pipeline of immunosuppressive drug  candidates for
treatment of autoimmune diseases and for use in the  prevention of
organ rejection in transplantation. Isotechnika looks to  become the
leader in development of immunosuppressant therapies.
Isotechnika's lead compound, ISA247 has completed an extension
protocol of a Canadian Phase III human clinical trial for the
treatment of  moderate to severe psoriasis and is currently involved
in a North American  Phase IIb human clinical trial for the
prevention of kidney graft rejection . The Company also has an
additional immunosuppressive compound in its drug  pipeline, TAFA93
which successfully completed Phase I clinical trials.
Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol ISA. More information on Isotechnika can be
found  at www.isotechnika.com.
Partnerships with Isotechnika Inc.
Isotechnika Inc. signed a collaboration agreement with Hoffman La
Roche on April 9, 2002, which licensed the worldwide rights to
develop and  commercialize ISA247 for all transplant indications.
On September 30, 2005, Isotechnika Inc. entered into an exclusive
worldwide licensing agreement with Atrium Medical Corporation for the
use  of ISA247 and TAFA93 specifically with drug eluting devices for
the non- systemic treatment of vascular, cardiovascular, target
vessel and tissue  disorders.
Isotechnika Inc. and Cellgate Inc. signed an option agreement on
April 25, 2006, granting Isotechnika the option to obtain an
exclusive  license to develop and commercialize conjugates consisting
of Cellgate's  patented transporter technology for the topical
delivery of ISA247 in  patients suffering from mild to moderate
psoriasis.
On May 25, 2006, Isotechnika Inc. signed an agreement with Lux
Biosciences, Inc. of Jersey City, New Jersey granting Lux Biosciences
worldwide rights to develop and commercialize Isotechnika's lead
drug,  ISA247 for the treatment and prophylaxis of all ophthalmic
diseases.
Forward-Looking Statements
This press release may contain forward-looking statements. Forward
looking statements, including the Company's belief as to the
potential of  its products, the Company's expectations regarding the
issuance of  additional patents and the Company's ability to protect
its intellectual  property, involve known and unknown risks and
uncertainties, which could  cause the Company's actual results to
differ materially from those in the  forward looking statements. Such
risks and uncertainties include, among  others, the availability of
funds and resources to pursue research and  development projects, the
ability to economically manufacture its products, the potential of
its products, the success and timely completion of clinical studies
and  trials, the Company's ability to successfully commercialize its
products,  the ability of the Company to defend its patents from
infringement by third  parties, and the risk that the Company's
patents may be subsequently shown  to be invalid or infringe the
patents of others. Investors should consult  the Company's quarterly
and annual filings with the Canadian commissions  for additional
information on risks and uncertainties relating to the  forward-
looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements.

Contact:

For further information: Dr. Randall Yatscoff, President & CEO,
Isotechnika Inc., +1-(780)-487-1600 (246), +1-(780)-484-4105 (fax),
ryatscoff@isotechnika.com; Stephanie Gillis-Paulgaard, Director,
Corporate Communications, Isotechnika Inc., +1-(780)-487-1600 (243),
+1-(780)-487-1500 (fax), sgillis-paulgaard@isotechnika.com

Weitere Storys: Isotechnika Inc.
Weitere Storys: Isotechnika Inc.